CytRx Corporation-Product Pipeline Review-2015

CytRx Corporation-Product Pipeline Review-2015

  • Products Id :- GMDHC07041CDB
  • |
  • Pages: 44
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

CytRx Corporation-Product Pipeline Review-2015


Global Markets Direct's, 'CytRx Corporation-Product Pipeline Review-2015', provides an overview of the CytRx Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CytRx Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of CytRx Corporation including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of CytRx Corporation's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the CytRx Corporation's pipeline products

Reasons To Buy

Evaluate CytRx Corporation's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of CytRx Corporation in its therapy areas of focus

Identify new drug targets and therapeutic classes in the CytRx Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of CytRx Corporation and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of CytRx Corporation

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of CytRx Corporation and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

CytRx Corporation Snapshot 5

CytRx Corporation Overview 5

Key Information 5

Key Facts 5

CytRx Corporation-Research and Development Overview 6

Key Therapeutic Areas 6

CytRx Corporation-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

CytRx Corporation-Pipeline Products Glance 12

CytRx Corporation-Late Stage Pipeline Products 12

Phase III Products/Combination Treatment Modalities 12

CytRx Corporation-Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

CytRx Corporation-Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

CytRx Corporation-Drug Profiles 16

aldoxorubicin hydrochloride 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

bafetinib 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Cyt-HiPoA 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Cyt-PLAT 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

CytRx Corporation-Pipeline Analysis 23

CytRx Corporation-Pipeline Products by Target 23

CytRx Corporation-Pipeline Products by Route of Administration 24

CytRx Corporation-Pipeline Products by Molecule Type 25

CytRx Corporation-Pipeline Products by Mechanism of Action 26

CytRx Corporation-Recent Pipeline Updates 27

CytRx Corporation-Dormant Projects 37

CytRx Corporation-Discontinued Pipeline Products 38

Discontinued Pipeline Product Profiles 38

INNO-305 38

tamibarotene 38

CytRx Corporation-Company Statement 39

CytRx Corporation-Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44

List of Tables

CytRx Corporation, Key Information 5

CytRx Corporation, Key Facts 5

CytRx Corporation-Pipeline by Indication, 2015 7

CytRx Corporation-Pipeline by Stage of Development, 2015 8

CytRx Corporation-Monotherapy Products in Pipeline, 2015 9

CytRx Corporation-Partnered Products in Pipeline, 2015 10

CytRx Corporation-Partnered Products/ Combination Treatment Modalities, 2015 11

CytRx Corporation-Phase III, 2015 12

CytRx Corporation-Phase II, 2015 13

CytRx Corporation-Phase I, 2015 14

CytRx Corporation-Preclinical, 2015 15

CytRx Corporation-Pipeline by Target, 2015 23

CytRx Corporation-Pipeline by Route of Administration, 2015 24

CytRx Corporation-Pipeline by Molecule Type, 2015 25

CytRx Corporation-Pipeline Products by Mechanism of Action, 2015 26

CytRx Corporation-Recent Pipeline Updates, 2015 27

CytRx Corporation-Dormant Developmental Projects,2015 37

CytRx Corporation-Discontinued Pipeline Products, 2015 38

CytRx Corporation, Subsidiaries 42

List of Figures

CytRx Corporation-Pipeline by Top 10 Indication, 2015 7

CytRx Corporation-Pipeline by Stage of Development, 2015 8

CytRx Corporation-Monotherapy Products in Pipeline, 2015 9

CytRx Corporation-Partnered Products in Pipeline, 2015 10

CytRx Corporation-Pipeline by Top 10 Target, 2015 23

CytRx Corporation-Pipeline by Top 10 Route of Administration, 2015 24

CytRx Corporation-Pipeline by Top 10 Molecule Type, 2015 25

CytRx Corporation-Pipeline Products by Top 10 Mechanism of Action, 2015 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of CytRx Corporation; CytRx Corporation - Key Therapeutics; CytRx Corporation - Pipeline Overview and Promising Molecules; CytRx Corporation - News; CytRx Corporation - Latest Updates; CytRx Corporation - Pipeline; CytRx Corporation - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101175
Site License
USD 3000 INR 202350
Corporate User License
USD 4500 INR 303525



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]